1-3 of 3
L. Benboubker
Close
Sort by
Journal Articles

A Multicenter Prospective Randomized Study Testing Non-Inferiority of Thalidomide 100 mg/day as Compared with 400 mg/day in Patients with Refractory/Relapsed Multiple Myeloma: First Results of the Final Analysis of the IFM 01-02 Study.

Ibrahim Yakoub-Agha, C. Hulin, C. Doyen, L. Benboubker, L. Voillat, K. Bouabdallah, G. Guillerm, P. Moreau, F. Maloisel, A.M. Stoppa, B. Pegourie, P. Rodon, M. Dib, P. Casassus, B. Slama, E. Voog, H. Jardel, P. Collet, M. Wettervald, A.M. Peny, P. Mineur, C. Duguet, R. Zerbib, T. Facon, J.Y. Mary
Journal: Blood
Blood (2005) 106 (11): 364.
https://doi.org/10.1182/blood.V106.11.364.364
Published: 2005
Journal Articles

Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup).

A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, M. Malphette, B. Lioure, B. Royer, B. Grosbois, J. Jaubert, P.M. Preux, M. Cogne, J.P. Fermand
Journal: Blood
Blood (2005) 106 (11): 421.
https://doi.org/10.1182/blood.V106.11.421.421
Published: 2005
Journal Articles

Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.

Thierry Facon, J.Y. Mary, C. Hulin, L. Benboubker, M. Attal, M. Renaud, J.L. Harousseau, B. Pegourie, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, C. Martin, P. Casassus, J. Jaubert, H. Jardel, B. Kolb, F. Bauters
Journal: Blood
Blood (2005) 106 (11): 780.
https://doi.org/10.1182/blood.V106.11.780.780
Published: 2005